Our Team

Rémi Droller

Strategic Advisor

Rémi Droller is a member of the executive board of Kurma Partners and holds a master's degree in molecular biology (Paris VI University) and a master's in finance and innovation management (Masternova - AgroParisTech).

After beginning his career at CDC Innovation between 2000 and 2003, he joined AGF Private Equity (now Idinvest Partners), where he developed the life sciences investment business and oversaw investments such as Novagali Pharma (listed on Euronext and acquired by Santen), Prosensa Therapeutics (listed on the Nasdaq and acquired by Biomarin), Vivacta (acquired by Novartis), Integragen (listed on Alternext) and Onxeo (listed on Euronext).

Rémi joined Kurma Partners in 2010 and is responsible for investments in AM Pharma (Netherlands), Orphazyme (Denmark), Oxthera (Sweden), Stat Diagnostica (Spain), Step Pharma (France) and Zealand Pharma (Denmark).